Caballero A Enrique
Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, USA.
Arch Med Res. 2005 May-Jun;36(3):241-9. doi: 10.1016/j.arcmed.2005.03.013.
Various groups at risk for type 2 diabetes have been identified, including individuals with family history of type 2 diabetes, obesity, prior gestational diabetes, polycystic ovary syndrome, metabolic syndrome, hypertension, dyslipidemia and particularly those with pre-diabetes (impaired glucose tolerance and/or impaired fasting glucose). To various degrees, all these groups have also been identified with significant vascular abnormalities that range from endothelial dysfunction and low-grade or sub-clinical inflammation to evident atherosclerosis. The mechanisms involved in establishing a link between the risk of type 2 diabetes and vascular dysfunction are multiple and complex. The presence in the circulation of various cytokines, hormones and substrates associated with increased visceral fat and insulin resistance, the frequent appearance of associated cardiovascular risk factors and/or the possibility of some genetically determined intrinsic vascular abnormalities are all explanatory mechanisms that are being evaluated in clinical research. Whereas the possibility of appreciating a significant reduction in cardiovascular outcomes in long-term prospective clinical trials in all these groups at risk for type 2 diabetes is still lacking, understanding these mechanisms and recognizing how various interventions may improve vascular health is a worthwhile area of research that may translate into important clinical strategies to reduce the burden of type 2 diabetes and cardiovascular disease.
已确定了各类2型糖尿病风险人群,包括有2型糖尿病家族史者、肥胖者、既往患妊娠糖尿病者、多囊卵巢综合征患者、代谢综合征患者、高血压患者、血脂异常者,尤其是糖尿病前期患者(糖耐量受损和/或空腹血糖受损)。在不同程度上,所有这些人群也都被发现存在显著的血管异常,范围从内皮功能障碍、低度或亚临床炎症到明显的动脉粥样硬化。建立2型糖尿病风险与血管功能障碍之间联系的机制是多方面且复杂的。循环中存在与内脏脂肪增加和胰岛素抵抗相关的各种细胞因子、激素和底物,相关心血管危险因素的频繁出现以及/或者某些基因决定的内在血管异常的可能性,都是临床研究中正在评估的解释机制。尽管在所有这些2型糖尿病风险人群的长期前瞻性临床试验中,仍缺乏能显著降低心血管结局的可能性,但了解这些机制并认识到各种干预措施如何改善血管健康,是一个有价值的研究领域,可能转化为重要的临床策略,以减轻2型糖尿病和心血管疾病的负担。